Methods for treating inflammation, autoimmune disorders and pain
Methods of treating, reducing, or preventing a disease or symptom relating to a disease such as oral mucositis, gingivitis, periodontitis, gastric mucositis, inflammatory fibrosis, gastritis, colitis, ileitis, Crohn's disease, chronic inflammatory intestinal disease, inflammatory bowel syndrome, chronic inflammatory bowel disease, celiac disease, ulcerative colitis, a gastric ulcer, a peptic ulcer, a buccal ulcer, a nasopharyngeal ulcer, an esophageal ulcer, a duodenal ulcer, a gastrointestinal ulcer, an autoimmune disorder, inflammation associated with cancer, cancer treatment, or radiation, and/or pain that include: identifying a patient in need of treatment; and administering a therapeutically effective amount of at least one cationic steroid antimicrobial (CSA), or a pharmaceutically acceptable salt thereof. Kits comprising such compositions and instructions on such methods are also contemplated herein.
1. A method of therapeutically treating or reducing acute or chronic inflammation and/or acute or chronic pain comprising:
identifying a patient in need of therapeutically treating or reducing acute or chronic inflammation and/or acute or chronic pain and
administering a therapeutically effective amount of at least one cationic steroid antimicrobial (CSA) compound of Formula (III), or a pharmaceutically acceptable salt thereof, to the patient in need thereof in order to therapeutically treat or reduce acute or chronic inflammation and/or acute or chronic pain:
wherein:
R 3 , R 7 , and R 12 are independently aminoalkyloxy or aminoalkylcarboxy; and
R 18 has the following structure:
—R 20 —(C═O)—N—R 21 R 22
where,
R 20 is a C 1 -C 10 alkyl, and
R 21 and R 22 are independently a hydrogen or a C 1 -C 24 alkyl, with the proviso that not more than one of R 21 or R 22 is a hydrogen.
2. The method of claim 1 , wherein the disease or the symptom of disease is selected from oral mucositis, gingivitis, periodontitis, gastric mucositis, gastritis, colitis, ileitis, Crohn's disease, chronic inflammatory intestinal disease, inflammatory bowel syndrome, chronic inflammatory bowel disease, celiac disease, ulcerative colitis, gastric ulcer, peptic ulcer, buccal ulcer, nasopharyngeal ulcer, esophageal ulcer, duodenal ulcer, gastrointestinal ulcer, cystic fibrosis.
3. The method of claim 1 , wherein
R 3 , R 7 , and R 12 are independently selected from the group consisting of (C 1 -C 18 ) aminoalkyloxy and (C 1 -C 18 ) aminoalkylcarboxy.
4. The method of claim 1 , wherein R 3 , R 7 , and R 12 are aminoalkyloxy.
5. The method of claim 1 , wherein R 3 , R 7 , and R 12 are aminoalkylcarboxy.
6. The method of claim 1 , wherein R 3 , R 7 , and R 12 are independently amino-C 3 -alkyloxy or amino-C 3 -alkyl-carboxy.
7. The method of claim 1 , wherein one of R 21 and R 22 C 1 -C 24 alkyl and another one of R 21 or R 22 is hydrogen.
8. The method of claim 1 , wherein the CSA compound, or a pharmaceutically acceptable salt thereof, is selected from the group consisting of:
and pharmaceutically acceptable salts thereof.
9. The method of claim 1 , wherein the CSA compound, or a pharmaceutically acceptable salt thereof, is
or a pharmaceutically acceptable salt thereof.
10. The method of claim 1 , wherein the pharmaceutically acceptable salt is selected from a hydrochloride salt, a mono-hydrochloride salt, a di-hydrochloride salt, a tri-hydrochloride salt, or a tetra-hydrochloride salt.
11. The method of claim 1 , further comprising administering a non-CSA antibiotic to the patient selected from the group consisting of an aminoglycoside, an ansamycin, a carbacephem, a carbapenem, a cephalosporin, a glycopeptide, a lincosamide, a lipopeptide, a macrolide, a monbactam, a nitrofuran, an oxazolidonone, a penicillin, a polypeptide, a quinolone, a sulfonamide, and a tetracycline.
12. The method of claim 1 , further comprising administering a non-CSA anti-inflammatory agent.
13. The method of claim 1 , wherein the CSA compound, or pharmaceutically acceptable salt thereof, is complexed with albumin or a surfactant.
14. The method of claim 13 , wherein the CSA compound is complexed with one or more poloxamer surfactants, a flake poloxamer and/or wherein the one or more poloxamer surfactants has a molecular weight of about 3600 g/mol for the central hydrophobic chain of polyoxypropylene and has about 70% polyoxyethylene content.
15. The method of claim 14 , wherein the ratio of the one or more poloxamer to CSA is between about 50 to 1 to about 1 to 50 or between about 30 to 1 to about 3 to 1.
16. The method of claim 1 , wherein the CSA compound or pharmaceutically acceptable salt thereof is selected by measuring a biomarker or subjecting a sample from the patient to a companion diagnostic device in the patient.
17. The method of claim 16 , wherein the biomarker is selected from the group consisting of IL-1A, IL-1B, IL-6, TLR2, TLR4, TLR6, TLR8, TLR9, TNFRSF1A, TNF, TNF-beta 1, CCL2, CXCR4, IRAK2, NFKB1, NFKB2, NFKB1A, and miR-29d.
18. A method of therapeutically treating or reducing acute or chronic inflammation and/or acute or chronic pain, as in claim 1 , comprising:
identifying a patient in need of therapeutically treating or reducing acute or chronic inflammation and/or acute or chronic pain and
administering a therapeutically effective amount of at least one cationic steroid antimicrobial (CSA) compound of Formula (III), or a pharmaceutically acceptable salt thereof, to the patient in need thereof in order to therapeutically treat or reduce acute or chronic inflammation and/or acute or chronic pain:
wherein:
R 3 R 7 , and R 12 are amino-C 3 -alkyloxy; and
R 18 has the following structure:
—R 20 —(C═O)—N—R 21 R 22
where,
R 20 is a C 5 alkyl; and
R 21 and R 22 are independently a hydrogen or a C 1 -C 24 alkyl and where not more than one of R 21 or R 22 is a hydrogen.